On January 8, 2026, the multinational biopharmaceutical giant AstraZeneca officially announced the appointment of a new Head of Investor Relations.... Read more
Category: Uncategorized
EU approves first-ever therapy to delay progression of Stage 3 Type 1 Diabetes
On January 12, 2026, the European Commission officially approved Sanofi’s Teizeild (teplizumab). This marks the first disease-modifying therapy authorized in... Read more
Nearly $1B in new venture capital floods biotech in the US and EU
January 2026 has marked a vibrant start for the biomedical venture capital market with the launch of three new funds,... Read more
Billion-Dollar Deal: Merck in talks to acquire oncology firm Revolution Medicines
The global pharmaceutical market is abuzz with reports that Merck & Co. (MSD) is in active negotiations to acquire Revolution... Read more
Alveus Therapeutics enters the obesity market with $160M Series A funding
Alveus Therapeutics has made its debut following a successful $160 million Series A financing round. Led by prominent healthcare investors... Read more
Novartis expands radiopharmaceutical network with new facility in Florida
Swiss drugmaker Novartis has unveiled plans to construct a new radioligand therapy (RLT) manufacturing plant in Winter Park, Florida. This... Read more
J&J strikes drug pricing deal with US Government and reveals expansion plans
Johnson & Johnson (J&J) has officially joined the ranks of biopharma giants striking "Most-Favored-Nation" (MFN) drug pricing agreements with the... Read more
Cancer cell therapy gains $250M momentum ahead of commercial launch
Orca Bio, a California-based biotech firm, has announced the successful raising of $250 million across its latest funding rounds. This... Read more
Promoting a sustainable organ donation and transplantation system in Vietnam
On January 9-10, 2026, Vietnamese and international medical experts convened to address the balance between advanced transplantation techniques and limited... Read more









